Short Interest in Compass Therapeutics, Inc. (NASDAQ:CMPX) Decreases By 13.8%

Compass Therapeutics, Inc. (NASDAQ:CMPX) saw a large drop in short interest in the month of March. As of March 31st, there was short interest totalling 1,620,000 shares, a drop of 13.8% from the March 15th total of 1,880,000 shares. Based on an average daily trading volume, of 485,500 shares, the short-interest ratio is currently 3.3 days. Approximately 2.0% of the company’s shares are sold short.

Institutional Investors Weigh In On Compass Therapeutics

Several large investors have recently bought and sold shares of CMPX. Tower Research Capital LLC TRC grew its holdings in shares of Compass Therapeutics by 577.2% in the 1st quarter. Tower Research Capital LLC TRC now owns 7,855 shares of the company’s stock valued at $26,000 after buying an additional 6,695 shares during the period. Jane Street Group LLC bought a new position in Compass Therapeutics during the third quarter worth about $33,000. XTX Topco Ltd bought a new position in shares of Compass Therapeutics during the 2nd quarter valued at about $35,000. Alliancebernstein L.P. acquired a new position in shares of Compass Therapeutics in the second quarter valued at approximately $36,000. Finally, ProShare Advisors LLC bought a new stake in Compass Therapeutics in the 2nd quarter valued at $38,000. Institutional investors own 68.43% of the company’s stock.

Compass Therapeutics Stock Down 0.6 %

NASDAQ CMPX traded down $0.01 on Tuesday, reaching $1.57. The company had a trading volume of 718,709 shares, compared to its average volume of 499,996. Compass Therapeutics has a 52 week low of $1.15 and a 52 week high of $3.62. The stock has a market cap of $216.02 million, a price-to-earnings ratio of -4.62 and a beta of 0.78. The stock’s 50 day moving average is $1.84 and its 200-day moving average is $1.73.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Thursday, March 21st. The company reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.09) by ($0.02). As a group, analysts forecast that Compass Therapeutics will post -0.48 EPS for the current year.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on CMPX. Wedbush reaffirmed an “outperform” rating and set a $8.00 price target on shares of Compass Therapeutics in a research note on Friday, March 22nd. HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Compass Therapeutics in a research report on Tuesday.

About Compass Therapeutics

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.